| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Exicure, Inc.$2.28
+0.11 (+5.07%)
D 38Pipeline Score Overvalued Biotech · Clinical
Market Cap
17.91 M
EPS
-0.77
P/E Ratio
-
Value Trade
8.34 K
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
312.00 K
Operating CF
-1.14 M
Total Assets
12.76 M
Total Liabilities
10.66 M
Equity
2.10 M
D/E Ratio
12,345
-6.33 %
Week
-25.07 %
1 Month
-23.64 %
3 Month
-31.96 %
6 Month
-98.93 %
5 Year
-99.38 %
All Time
Cash Data
Cash Position
2.60 M
Monthly Burn
381.00 K
Runway
6.4 mo
Burn Trend
SEC Filing
May 29, 2026
Overview
Volume
5.68 K
52 Week Range
2.63 - 10.80
% held by Insiders
34.01 %
% held by Institutions
1.81 %
Enterprise Value
14.34 M
Total Shares
6.37 M
Short %
0.49 %
Float Shares
4.28 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D38
Pipeline Score $6M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.3x
rNPV / MCap Top 52%
Micro Cap (rank 435 of 905)
Percentile RankExicure, Inc. faces pipeline headwinds (38/100), with $2.8B risk-adjusted pipeline value, led by TG-0054 combined with G-CSF in Multiple Myeloma (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TG-0054 combined with G-CSF Small molecule | Multiple Myeloma | Phase 2 | NCT02104427 | 19% | $921M | COMPLETED | 12 | - | - | Nov 1, 2015 | - | Apr 19, 2021 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Burixafor (GPC-100) | Multiple Myeloma,Sickle Cell Disease,Acute Myeloid Leukemia | Phase 2 | 2025-10-06 | |||
Burixafor (GPC-100) | Multiple Myeloma,Sickle Cell Disease,Acute Myeloid Leukemia | Phase 2 | 2025-10-06 | |||
Burixafor (GPC-100) | Multiple Myeloma,Sickle Cell Disease,Acute Myeloid Leukemia | Phase 2 | 2025-10-06 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in XCUR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Exicure, Inc. (XCUR) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
XCUR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
XCUR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
XCUR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
XCUR Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
XCUR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
XCURExicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
Exicure, Inc. received a notification from Nasdaq indicating non-compliance with the minimum stockholders' equity requirement. The company reported equity of approximately $2.1 million, below the $2.5 million threshold. Exicure plans to submit a compliance plan within 45 days and is exploring options to improve its financial standing. The notification does not immediately affect its stock listing.
Read more →XCURExicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
Exicure, Inc. received a delinquency notice from Nasdaq due to a delay in filing its Quarterly Report on Form 10-Q for Q1 2026. The delay was attributed to changes in financial reporting personnel. However, the company has since filed the report and believes it has regained compliance with Nasdaq regulations. Exicure is also exploring strategic alternatives following a restructuring.
Read more →XCURExicure, Inc. Reports Full Year 2025 Financial Results
Exicure, Inc. reported its financial results for 2025, revealing a net loss of $4.9 million, an improvement from the previous year's loss of $9.7 million. The company faces liquidity challenges, with cash reserves insufficient to sustain operations for the next year. Increased expenses were noted due to the acquisition of GPCR Therapeutics USA Inc., necessitating additional financing to support ongoing operations and strategic alternatives.
Read more →XCURExicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
Exicure, Inc. announced the publication of a Phase 2 study in the Annals of Hematology, highlighting the efficacy of burixafor in rapidly mobilizing stem cells in patients with multiple myeloma and lymphoma undergoing transplant. The study showed that 92% of participants achieved the primary endpoint, with significant increases in white blood cell subsets. Burixafor's rapid mobilization profile may simplify treatment logistics and reduce patient burden.
Read more →XCURExicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
Exicure, Inc. will present data from its Phase 2 trial of burixafor at the 2026 Tandem Meetings. The trial evaluated burixafor's effectiveness in mobilizing hematopoietic progenitor cells for patients with multiple myeloma undergoing autologous transplantation. The study reported a high success rate in achieving the primary endpoint, highlighting burixafor's potential as a reliable mobilization strategy.
Read more →XCURExicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
Exicure, Inc. announced positive results from its Phase 2 trial of burixafor for multiple myeloma. Approximately 90% of participants achieved the primary endpoint for hematopoietic progenitor cell mobilization. The combination therapy was well tolerated, showing a rapid mobilization of cells and an excellent safety profile. These findings were presented at the 67th ASH Annual Meeting.
Read more →XCURExicure, Inc. Reports Third Quarter 2025 Financial Results
Exicure, Inc. reported its financial results for Q3 2025, showing a net loss of $2.4 million, up from $1.1 million in Q3 2024. The company’s cash position has declined to $4.4 million, raising concerns about its ability to fund operations. Increased expenses were attributed to the acquisition of GPCR Therapeutics USA Inc., and management indicated a need for substantial additional financing.
Read more →XCURNew Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
Exicure, Inc. announced that results from its Phase 2 study of burixafor will be presented at the 67th ASH Annual Meeting. The study demonstrated an excellent safety profile and effective mobilization of hematopoietic progenitor cells in multiple myeloma patients. The oral presentation will take place on December 8, 2025, highlighting promising data.
Read more →XCURExicure Highlights Recent Achievements and Near-term Strategic Priorities
Exicure, Inc. has reported significant progress on its lead program, burixafor (GPC-100), which is nearing a key Phase 2 trial readout for multiple myeloma. Interim results indicate 100% success in stem cell mobilization. The company is also preparing to expand burixafor's application to other diseases and has strengthened its leadership team with experienced professionals in drug development.
Read more →Competitive Position
How XCUR ranks across every disease it competes inCompetitive Position is a premium feature
See how XCUR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial